Novacyt S.A. Molecular respiratory panel ready for US market (9023O)
07 Octubre 2019 - 1:00AM
UK Regulatory
TIDMNCYT
RNS Number : 9023O
Novacyt S.A.
07 October 2019
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
New molecular respiratory panel ready for the US market
Multiplex test identifies up to 37 respiratory pathogens
Paris, France and Camberley, UK - 7 October 2019 - Novacyt
(ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, today announces the succesful development of
a new molecular diagnostic multiplex test for respiratory
infections, which is ready for launch in North America in time for
the US cold and flu season.
Novacyt's molecular business unit Primerdesign, has completed
the design and development of the molecular respiratory panel based
on a 384 well plate format for use by its North American business
partner in their CLIA approved diagnostic testing laboratory
network. Primerdesign has designed the multiplex test to identify
37 respiratory pathogens, which makes it one of the most
comprehensive respiratory panels available in the market today. In
addition to identifying a large number of respiratory disease
pathogens, the new diagnostic product has been designed with
proprietary freeze-drying technology to stabilise the product to
optimise its ease of use and performance.
Primerdesign will supply this product under a five year
manufacturing agreement as its partner launches the new respiratory
panel in the US market through its own clinical testing
laboratories to provide a Laboratory Developed Diagnostic test
result for its customers. The initial order for $105,000 has been
received by Primerdesign to supply its US partner.
The global respiratory disease testing market was valued in 2016
at US$5.0billion(1) and is forecast to grow at a rate of 3.3% per
annum. The US market accounts for more than 30% of the global
respiratory testing market.
Graham Mullis, Group CEO commented:
"This development marks a significant step forward in the
Group's B2B strategy by providing our North American business
partner with the opportunity to access the significant demand for
the US seasonal respiratory testing market, which typically runs
from September to April. It also demonstrates the increasing
capability of Novacyt's R&D team as it broadens its product
portfolio and builds the skills to develop more complex products.
The rapid development of this new multiplex molecular diagnostic
panel shows the power of our intergrated research, development and
commercialisation team. We believe this will be an important tool
for clinicians to better serve patient needs. This is just one of a
number of different assay panels being developed by
Primerdesign."
[1] Respiratory Disease Testing/diagnostics market, Industry
Report, 2025 Grand View Research
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com /
victoria.fostermitchell@fticonsulting.com
Mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays
and reagents worldwide. The Group directly serves oncology,
microbiology, haematology and serology markets as do its global
partners, which include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEASEKEDANFFF
(END) Dow Jones Newswires
October 07, 2019 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024